Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model

Annals of Clinical Biochemistry

Volumn 52, Issue 2, 2015, Pages 237-244

  Lund, Flemming ^a   Petersen, Per Hyltoft ^a,b   Fraser, Callum G ^c   Sölétormos, György ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

biological variation; log normal (Gaussian) distribution; monitoring; normal (Gaussian) distribution; reference change value; Simulation models; unidirectional differences

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CALCULATION; COMPUTER SIMULATION; HUMAN; MEASUREMENT; NORMAL DISTRIBUTION; NORMAL HUMAN; PRIORITY JOURNAL; PROBABILITY; SIMULATION; ALGORITHM; BIOLOGICAL MODEL; CLINICAL CHEMISTRY; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL;

ALGORITHMS; BIOMARKERS; CHEMISTRY, CLINICAL; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NORMAL DISTRIBUTION; REPRODUCIBILITY OF RESULTS;

EID: 84924810780     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563214534636     Document Type: Article

References (13)

1. Harris EK,Yasaka T.On the calculation of a “reference change” for comparing two consecutive measurements.Clin Chem. 1983;29:25-30
2. Ricós C,Garcia-Lario JV,Alvares V, et al.Biological variation database on biological variation: pros, cons and progress.Scand J Clin Lab Invest. 1999;59:491-500
3. Fraser CGBiological variation: from principles to practice. Washington, DC: AACC Press; 2001:
4. Fokkema MR,Hermann Z,Muskiet FAJ, et al.Reference change values for brain natriuretic peptides revisited.Clin Chem. 2006;52:1602-1603
5. Klersy C,d'Ezril GVM,Barassi A, et al.Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type batriuretic peptide.Clin Chim Act. 2012;413:544-547
6. Møller HJ,Hyltoft Petersen P,Rejnmark L, et al.Biological variation of soluble CD163.Scand J Clin Lab Invest. 2003;63:15-22
7. Tuxen MK,Sölétormos G,Hyltoft Petersen P, et al.Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer.Clin Chem Lab Med. 2001;39:531-538
8. Limpert E,Stahel WA,Abbt M.Log-normal distribution across the sciences: keys and clues.BioScience. 2001;51:341-352
9. Bliss CIStatistics in biology. New York: McGraw-Hill Book Company; 1967:
10. Sölétormos G,Hyltoft Petersen P,Dombernowsky P.Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data.Clin Chem. 2000;46:939-949
11. Petersen PH,Sölétormos G,Pedersen MF, et al.Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off.Clin Chem Lab Med. 2011;49:303-310
12. Lund F,Hyltoft Petersen P,Pedersen MF, et al.Criteria to interpret cancer biomarker increments crossing the recommended cut-off compared in a simulation model focusing on false positive signals and tumour detection time.Clin Chim Act. 2014;431:192-197
13. Sölétormos G,Duffy MJ,Hayes DF, et al.Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.Clin Chem. 2013;59:52-59